State of the Art Review on the Treatment of Psoriatic Disease

Eleftherios Pelechas; Evripidis Kaltsonoudis; Michalis P Migkos; Nikolaos Koletsos; Panagiota G Karagianni; Alexandros A Drosos; Paraskevi V Voulgari

doi:10.31138/mjr.040123.sot

State of the Art Review on the Treatment of Psoriatic Disease

Mediterr J Rheumatol. 2024 Jan 31;35(1):66-72. doi: 10.31138/mjr.040123.sot. eCollection 2024 Mar.

Authors

Eleftherios Pelechas¹, Evripidis Kaltsonoudis¹, Michalis P Migkos¹, Nikolaos Koletsos¹, Panagiota G Karagianni², Alexandros A Drosos¹, Paraskevi V Voulgari¹

Affiliations

¹ Department of Rheumatology, Medical School, University of Ioannina, Ioannina, Greece.
² Department of Microbiology, Medical School, University of Ioannina, Ioannina, Greece.

Abstract

Introduction: Psoriasis is an inflammatory skin disease that in some cases is accompanied by systemic manifestations. Given the varied clinical manifestations, the term psoriatic disease probably better reflects the clinical picture of these patients.

Literature review: In most cases, the skin lesions precede joint involvement as well as other potentially involved organs such as the intestine and the eye. Various immune-mediated cellular pathways such as that of TNFα, IL-23, IL-17 as well as other cytokines are involved in the pathophysiology of the psoriatic disease.

Future insights: A better understanding of the way they interfere with our immune system has led to remarkably better disease control and outcomes. This review aims to highlight the newest treatments for psoriatic disease, which are expected to significantly reduce unmet needs and treatment gaps.

Keywords: IL inhibitors; JAK inhibitors; TYK inhibitors; psoriasis; psoriatic arthritis; psoriatic disease.

Publication types

Review